China: National Medical Products Administration (NMPA)

The national authority

The National Medical Products Administration is China's national regulator for drugs, medical devices, and cosmetics. It operates under the State Administration for Market Regulation, and its technical review work is performed by affiliated centers - the Center for Drug Evaluation for medicines and the Center for Medical Device Evaluation for devices.

China's market is the second largest in the world for medical products, and the NMPA's modernization over the past decade - faster reviews, alignment with international standards, and membership in the international harmonization council - has reshaped global development strategies.

How products enter the market

Drugs require a marketing authorization following technical review of quality, nonclinical, and clinical evidence. Since the reform of the generic-drug system, generics must demonstrate quality and efficacy equivalence to the reference product, raising the bar for the large domestic generic sector.

Medical devices are classified into three classes by risk: Class I devices require only a filing (record-notification), while Classes II and III require registration with progressively deeper technical review. In-vitro diagnostics are regulated as devices under the same class logic.

Foreign products follow the same routes but historically needed local clinical data; reforms now accept overseas trial data under defined conditions, which has substantially shortened the gap between global and Chinese approvals.

Speeding access

China operates several expedited channels: priority review for drugs addressing urgent clinical needs and serious diseases, conditional approval for products treating life-threatening conditions where early evidence is promising, and breakthrough therapy designations.

Special import pathways allow clinically urgent products approved abroad but not yet in China to be used in designated settings, notably in designated zones such as the Boao medical tourism pilot zone in Hainan.

Traditional Chinese medicine products follow a dedicated registration classification system reflecting their distinct evidence base.

Using this profile

Administrators and researchers should treat the English-language NMPA portal as an orientation layer: announcements and high-level guidance appear in English, but the operational record - approval databases, technical guidelines, review reports - is overwhelmingly in Chinese.

For cross-country comparison: China's system now structurally resembles the international model (risk-classed devices, marketing authorization holder system, expedited pathways) while retaining distinctive features, including the scale of its domestic industry and the role of provincial-level administrations in lower-risk device classes. The authority portal listed in this profile's internal reference record is the primary source for current rules.